Q-omics provides the consensus-scored LHB profile across patient tissues and cancer cell-line models. LHB expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LHB is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, LHB protein abundance shows 21,161 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where LHB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LHB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LHB survival associations across molecular data types. LHB RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LHB RNA expression–survival associations across cancer types. High LHB expression shows unfavorable associations in ACC, KIRC, UVM, MESO, SKCM and COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LHB RNA expression.
This table summarizes LHB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LHB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LHB shows higher tumor expression in HNSC, COAD, LUAD, BLCA, KIRP and THCA. The HNSC box plot shows higher LHB RNA expression in tumor versus normal tissue (log2 FC = +0.840, t-test p < 0.001).
This table shows molecular features associated with LHB in patient tissues and cancer cell lines. In patient samples, LHB shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LHB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
